We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Johnson and Johnson | NYSE:JNJ | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.92 | -0.63% | 145.90 | 147.175 | 145.95 | 146.70 | 6,182,981 | 00:52:45 |
From Apr 2022 to Apr 2024
By Colin Kellaher
Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Monday said the U.S. Food and Drug Administration approved the expanded use of its blockbuster anti-inflammatory drug Stelara to treat children ages six and older with active psoriatic arthritis.
The company said two of the four FDA-approved indications for Stelara now include pediatric patients.
The agency first approved Stelara in September 2009 for adults with moderate to severe plaque psoriasis, and the drug has since been cleared for use in psoriatic arthritis, Crohn's disease and ulcerative colitis.
Johnson & Johnson reported second-quarter Stelara sales of nearly $2.6 billion.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 01, 2022 09:51 ET (13:51 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Johnson and Johnson Chart |
1 Month Johnson and Johnson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
